Log in

TSE:HLSHLS Therapeutics Stock Price, Forecast & News

C$19.70
-1.14 (-5.47 %)
(As of 06/2/2020 04:31 AM ET)
Add
Compare
Today's Range
C$19.26
Now: C$19.70
C$20.49
50-Day Range
C$17.15
MA: C$18.66
C$20.84
52-Week Range
C$12.91
Now: C$19.70
C$25.92
Volume40,039 shs
Average Volume45,879 shs
Market CapitalizationC$625.28 million
P/E RatioN/A
Dividend Yield0.96%
BetaN/A
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.94 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone647-495-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$54.88 million
Cash FlowC$1.36 per share
Book ValueC$5.34 per share

Profitability

Miscellaneous

Employees46
Market CapC$625.28 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive HLS News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

HLS Therapeutics (TSE:HLS) Frequently Asked Questions

How has HLS Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

HLS Therapeutics' stock was trading at C$18.75 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HLS shares have increased by 5.1% and is now trading at C$19.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of HLS Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HLS Therapeutics.

When is HLS Therapeutics' next earnings date?

HLS Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for HLS Therapeutics.

How were HLS Therapeutics' earnings last quarter?

HLS Therapeutics Inc (TSE:HLS) released its earnings results on Thursday, May, 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.30. The firm had revenue of $18.65 million for the quarter, compared to analyst estimates of $18.48 million. View HLS Therapeutics' earnings history.

How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics?

HLS Therapeutics announced a quarterly dividend on Thursday, March 19th. Stockholders of record on Thursday, April 30th will be given a dividend of 0.05 per share on Monday, June 15th. This represents a $0.20 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Wednesday, April 29th. View HLS Therapeutics' dividend history.

Has HLS Therapeutics been receiving favorable news coverage?

News coverage about HLS stock has been trending very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. HLS Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutHLS Therapeutics.

Who are some of HLS Therapeutics' key competitors?

What other stocks do shareholders of HLS Therapeutics own?

Who are HLS Therapeutics' key executives?

HLS Therapeutics' management team includes the following people:
  • Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 58)
  • Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 62)
  • Mr. Gilbert Godin, Pres & COO (Age 60)
  • Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 48)
  • Mr. Ryan C. Lennox, Gen. Counsel & Corp. Sec. (Age 39)

What is HLS Therapeutics' stock symbol?

HLS Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HLS."

How do I buy shares of HLS Therapeutics?

Shares of HLS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is HLS Therapeutics' stock price today?

One share of HLS stock can currently be purchased for approximately C$19.70.

How big of a company is HLS Therapeutics?

HLS Therapeutics has a market capitalization of C$625.28 million and generates C$54.88 million in revenue each year. HLS Therapeutics employs 46 workers across the globe.

What is HLS Therapeutics' official website?

The official website for HLS Therapeutics is www.hlstherapeutics.com.

How can I contact HLS Therapeutics?

The company can be reached via phone at 647-495-9000.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.